Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Geriatrics Reports
Published in: Current Geriatrics Reports 2/2012

01-06-2012 | Biomarkers in the Classification of Biological Health and Disease Aging (Y Shen, Section Editor)

Spectrin Breakdown Products (SBDPs) as Potential Biomarkers for Neurodegenerative Diseases

Authors: Xiao-Xin Yan, Andreas Jeromin

Published in: Current Geriatrics Reports | Issue 2/2012

Login to get access

Abstract

The expected lifespan of the world’s human population grows rapidly thanks to the great advance in modern medicine. While more and more body system diseases become treatable and curable, age-related neurodegenerative diseases remain poorly understood mechanistically, and are desperately in need of preventive and therapeutic interventions. Biomarker development consists of a key part of concerted efforts in combating neurodegenerative diseases. In many chronic neurodegenerative conditions, neuronal damage/death occurs long before the onset of disease symptoms, and abnormal proteolysis may either play an active role or be an accompanying event of neuronal injury. Increased spectrin cleavage yielding elevated spectrin breakdown products (SBDPs) by calcium-sensitive proteases such as calpain and caspases has been established in conditions associated with acute neuronal damage such as traumatic brain injury (TBI). In this article, we review literature regarding spectrin expression and metabolism in the brain, and propose a potential use of SBDPs as biomarkers for neurodegenerative diseases such as Alzheimer’s disease.
Literature
1.
Marchesi VT, Steers Jr E. Selective solubilization of a protein component of the red cell membrane. Science. 1968;159:203–4.PubMedCrossRef
2.
Goodman SR, Zagon IS, Whitfield CF, et al. A spectrin-like protein from mouse brain membranes: immunological and structural correlations with erythrocyte spectrin. Cell Motil. 1983;3:635–47.PubMedCrossRef
3.
Bennett V, Lambert S. The spectrin skeleton: from red cells to brain. J Clin Invest. 1991;87:1483–9.PubMedCrossRef
4.
Baines AJ. Evolution of spectrin function in cytoskeletal and membrane networks. Biochem Soc Trans. 2009;37:796–803.PubMedCrossRef
5.
Ikeda Y, Dick KA, Weatherspoon MR, et al. Spectrin mutations cause spinocerebellar ataxia type 5. Nat Genet. 2006;38:184–90.PubMedCrossRef
6.
Lynch G, Baudry M. Brain spectrin, calpain and long-term changes in synaptic efficacy. Brain Res Bull. 1987;18:809–15.PubMedCrossRef
7.
Czogalla A, Sikorski AF. Spectrin and calpain: a 'target' and a 'sniper' in the pathology of neuronal cells. Cell Mol Life Sci. 2005;62:1913–24.PubMedCrossRef
8.
Pineda JA, Lewis SB, Valadka AB, et al. Clinical significance of alphaII-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury. J Neurotrauma. 2007;24:354–66.PubMedCrossRef
9.
Weiss ES, Wang KK, Allen JG, et al. Alpha II-spectrin breakdown products serve as novel markers of brain injury severity in a canine model of hypothermic circulatory arrest. Ann Thorac Surg. 2009;88:543–50.PubMedCrossRef
10.
Zhang Z, Larner SF, Liu MC, et al. Multiple alphaII-spectrin breakdown products distinguish calpain and caspase dominated necrotic and apoptotic cell death pathways. Apoptosis. 2009;14:1289–98.PubMedCrossRef
11.
Mondello S, Robicsek SA, Gabrielli A, et al. αII-spectrin breakdown products (SBDPs): diagnosis and outcome in severe traumatic brain injury patients. J Neurotrauma. 2010;27:1203–13.PubMedCrossRef
12.
Peterson C, Vanderklish P, Seubert P, et al. Increased spectrin proteolysis in fibroblasts from aged and Alzheimer donors. Neurosci Lett. 1991;121:239–43.PubMedCrossRef
13.
Masliah E, Iimoto DS, Saitoh T, et al. Increased immunoreactivity of brain spectrin in Alzheimer disease: a marker for synapse loss? Brain Res. 1990;531:36–44.PubMedCrossRef
14.
Mangeat PH. Interaction of biological membranes with the cytoskeletal framework of living cells. Biol Cell. 1988;64:261–81.PubMedCrossRef
15.
Palek J, Lambert S. Genetics of the red cell membrane skeleton. Semin Hematol. 1990;27:290–332.PubMed
16.
Winkelmann JC, Forget BG. Erythroid and nonerythroid spectrins. Blood. 1993;81:3173–85.PubMed
17.
Delaunay J. The molecular basis of hereditary red cell membrane disorders. Blood Rev. 2007;21:1–20.PubMedCrossRef
18.
Gallagher PG. Update on the clinical spectrum and genetics of red blood cell membrane disorders. Curr Hematol Rep. 2004;3:85–91.PubMed
19.
Karinch AM, Zimmer WE, Goodman SR. The identification and sequence of the actin-binding domain of human red blood cell beta-spectrin. J Biol Chem. 1990;265:11833–40.PubMed
20.
Fowler V, Taylor DL. Spectrin plus band 4.1 cross-link actin. Regulation by micromolar calcium. J Cell Biol. 1980;85:361–76.PubMedCrossRef
21.
Davis JQ, Bennett V. Brain ankyrin. Purification of a 72,000 Mr spectrin-binding domain. J Biol Chem. 1984;259:1874–81.PubMed
22.
Coleman TR, Harris AS, Mische SM, et al. Beta spectrin bestows protein 4.1 sensitivity on spectrin-actin interactions. J Cell Biol. 1987;104:519–26.PubMedCrossRef
23.
Fowler VM, Bennett V. Erythrocyte membrane tropomyosin. Purification and properties. J Biol Chem. 1984;259:5978–89.PubMed
24.
Fowler VM. Tropomodulin: a cytoskeletal protein that binds to the end of erythrocyte tropomyosin and inhibits tropomyosin binding to actin. J Cell Biol. 1990;111:471–81.PubMedCrossRef
25.
Gardner K, Bennett V. Modulation of spectrin-actin assembly by erythrocyte adducin. Nature. 1987;328:359–62.PubMedCrossRef
26.
Morris CE. Mechanoprotection of the plasma membrane in neurons and other non-erythroid cells by the spectrin-based membrane skeleton. Cell Mol Biol Lett. 2001;6:703–20.PubMed
27.
Mastrangelo M, Leuzzi V. Genes of early-onset epileptic encephalopathies: from genotype to phenotype. Pediatr Neurol. 2012;46:24–31.PubMedCrossRef
28.
Fukushima Y, Byers MG, Watkins PC, et al. Assignment of the gene for beta-spectrin (SPTB) to chromosome 14q23----q24.2 by in situ hybridization. Cytogenet Cell Genet. 1990;53:232–3.PubMedCrossRef
29.
Dhermy D, Galand C, Bournier O, et al. Hereditary spherocytosis with spectrin deficiency related to null mutations of the beta-spectrin gene. Blood Cells Mol Dis. 1998;24:251–61.PubMedCrossRef
30.
Gallagher PG, Petruzzi MJ, Weed SA, et al. Mutation of a highly conserved residue of betaI spectrin associated with fatal and near-fatal neonatal hemolytic anemia. J Clin Invest. 1997;99:267–77.PubMedCrossRef
31.
Stankewich MC, Tse WT, Peters LL, et al. A widely expressed betaIII spectrin associated with Golgi and cytoplasmic vesicles. Proc Natl Acad Sci U S A. 1998;95:14158–63.PubMedCrossRef
32.
Berghs S, Aggujaro D, Dirkx Jr R, et al. betaIV spectrin, a new spectrin localized at axon initial segments and nodes of ranvier in the central and peripheral nervous system. J Cell Biol. 2000;151:985–1002.PubMedCrossRef
33.
Stabach PR, Morrow JS. Identification and characterization of beta V spectrin, a mammalian ortholog of Drosophila beta H spectrin. J Biol Chem. 2000;275:21385–95.PubMedCrossRef
34.
Jiang X, Gillen S, Esposito I, et al. Reduced expression of the membrane skeleton protein beta1-spectrin (SPTBN1) is associated with worsened prognosis in pancreatic cancer. Histol Histopathol. 2010;25:1497–506.PubMed
35.
Bennett V, Davis J, Fowler WE. Brain spectrin, a membrane-associated protein related in structure and function to erythrocyte spectrin. Nature. 1982;299:126–31.PubMedCrossRef
36.
Bennett V, Healy J. Organizing the fluid membrane bilayer: diseases linked to spectrin and ankyrin. Trends Mol Med. 2008;4:28–36.CrossRef
37.
Goodman SR, Zimmer WE, Clark MB, et al. Brain spectrin: of mice and men. Brain Res Bull. 1995;36:593–606.PubMedCrossRef
38.
Zagon IS, Higbee R, Riederer BM, Goodman SR. Spectrin subtypes in mammalian brain: an immunoelectron microscopic study. J Neurosci. 1986;6:2977–86.PubMed
39.
Susuki K, Raphael AR, Ogawa Y, et al. Schwann cell spectrins modulate peripheral nerve myelination. Proc Natl Acad Sci U S A. 2011;108:8009–80014.PubMedCrossRef
40.
Koenig E, Kinsman S, Repasky E, Sultz L. Rapid mobility of motile varicosities and inclusions containing alpha-spectrin, actin, and calmodulin in regenerating axons in vitro. J Neurosci. 1985;5:715–29.PubMed
41.
Bloch RJ, Morrow JS. An unusual beta-spectrin associated with clustered acetylcholine receptors. J Cell Biol. 1989;8:481–93.CrossRef
42.
Sunderland WJ, Son YJ, Miner JH, et al. The presynaptic calcium channel is part of a transmembrane complex linking a synaptic laminin (alpha4beta2gamma1) with non-erythroid spectrin. J Neurosci. 2000;20:1009–19.PubMed
43.
Lacas-Gervais S, Guo J, Strenzke N, et al. BetaIVSigma1 spectrin stabilizes the nodes of Ranvier and axon initial segments. J Cell Biol. 2004;166:983–90.PubMedCrossRef
44.
Hülsmeier J, Pielage J, Rickert C, et al. Distinct functions of alpha-spectrin and beta-spectrin during axonal pathfinding. Development. 2007;134:713–22.PubMedCrossRef
45.
Yang Y, Ogawa Y, Hedstrom KL, Rasband MN. betaIV spectrin is recruited to axon initial segments and nodes of Ranvier by ankyrin G. J Cell Biol. 2007;176:509–19.PubMedCrossRef
46.
Voas MG, Lyons DA, Naylor SG, et al. alphaII-spectrin is essential for assembly of the nodes of Ranvier in myelinated axons. Curr Biol. 2007;7:562–8.CrossRef
47.
Puchkov D. Leshchyns'ka I, Nikonenko AG, et al.: NCAM/spectrin complex disassembly results in PSD perforation and postsynaptic endocytic zone formation. Cereb Cortex. 2011;21:2217–32.PubMedCrossRef
48.
Pielage J, Fetter RD, Davis GW. A postsynaptic spectrin scaffold defines active zone size, spacing, and efficacy at the Drosophila neuromuscular junction. J Cell Biol. 2006;175:491–503.PubMedCrossRef
49.
Ramser EM, Buck F, Schachner M, Tilling T. Binding of alphaII spectrin to 14-3-3beta is involved in NCAM-dependent neurite outgrowth. Mol Cell Neurosci. 2010;45:66–74.PubMedCrossRef
50.
Stankewich MC, Gwynn B, Ardito T, et al. Targeted deletion of betaIII spectrin impairs synaptogenesis and generates ataxic and seizure phenotypes. Proc Natl Acad Sci U S A. 2010;107:6022–7.PubMedCrossRef
51.
Westphal D, Sytnyk V, Schachner M. Leshchyns'ka I: Clustering of the neural cell adhesion molecule (NCAM) at the neuronal cell surface induces caspase-8- and -3-dependent changes of the spectrin meshwork required for NCAM-mediated neurite outgrowth. J Biol Chem. 2010;285:42046–57.PubMedCrossRef
52.
Gao Y, Perkins EM, Clarkson YL, et al. β-III spectrin is critical for development of Purkinje cell dendritic tree and spine morphogenesis. J Neurosci. 2011;31:16581–90.PubMedCrossRef
53.
Nestor MW, Cai X, Stone MR, et al. The actin binding domain of βI-spectrin regulates the morphological and functional dynamics of dendritic spines. PLoS. 2011;6:e16197.
54.
Lorenzo DN, Li MG, Mische SE, et al. Spectrin mutations that cause spinocerebellar ataxia type 5 impair axonal transport and induce neurodegeneration in Drosophila. J Cell Biol. 2010;189:143–58.PubMedCrossRef
55.
Perkins EM, Clarkson YL, Sabatier N, et al. Loss of beta-III spectrin leads to Purkinje cell dysfunction recapitulating the behavior and neuropathology of spinocerebellar ataxia type 5 in humans. J Neurosci. 2010;30:4857–67.PubMedCrossRef
56.
Nath R, Raser KJ, Stafford D, et al. Non-erythroid alpha-spectrin breakdown by calpain and interleukin 1 beta-converting-enzyme-like protease(s) in apoptotic cells: contributory roles of both protease families in neuronal apoptosis. Biochem J. 1996;319:683–90.PubMed
57.
Hsu YJ, Zimmer WE, Goodman SR. Erythrocyte spectrin’s chimeric E2/E3 ubiquitin conjugating/ligating activity. Cell Mol Biol (Noisy-le-grand). 2005;51:187–93.
58.
Wang KK, Posmantur R, Nath R, et al. Simultaneous degradation of alphaII- and betaII-spectrin by caspase 3 (CPP32) in apoptotic cells. J Biol Chem. 1998;273:22490–7.PubMedCrossRef
59.
Zhao X, Newcomb JK, Pike BR, et al. Novel characteristics of glutamate-induced cell death in primary septohippocampal cultures: relationship to calpain and caspase-3 protease activation. J Cereb Blood Flow Metab. 2000;20:550–62.PubMedCrossRef
60.
Newcomb-Fernandez JK, Zhao X, Pike BR, et al. Concurrent assessment of calpain and caspase-3 activation after oxygen-glucose deprivation in primary septo-hippocampal cultures. J Cereb Blood Flow Metab. 2001;21:1281–94.PubMedCrossRef
61.
Pike BR, Flint J, Dave JR, et al. Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived alphaII-spectrin in cerebral spinal fluid after middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab. 2004;24:98–106.PubMedCrossRef
62.
Gold MS, Kobeissy FH, Wang KK, et al. Methamphetamine- and trauma-induced brain injuries: comparative cellular and molecular neurobiological substrates. Biol Psychiatry. 2009;66:118–27.PubMedCrossRef
63.
Vanderklish PW, Bahr BA. The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. Int J Exp Pathol. 2000;81:323–239.PubMedCrossRef
64.
Bahr BA, Tiriveedhi S, Park GY, Lynch G. Induction of calpain-mediated spectrin fragments by pathogenic treatments in long-term hippocampal slices. J Pharmacol Exp Ther. 1995;273:902–8.PubMed
65.
Seubert P, Larson J, Oliver M, et al. Stimulation of NMDA receptors induces proteolysis of spectrin in hippocampus. Brain Res. 1988;460:189–94.PubMedCrossRef
66.
Siman R, Noszek JC, Kegerise C. Calpain I activation is specifically related to excitatory amino acid induction of hippocampal damage. J Neurosci. 1989;9:1579–90.PubMed
67.
Bi X, Chang V, Siman R, et al. Regional distribution and time-course of calpain activation following kainate-induced seizure activity in adult rat brain. Brain Res. 1996;726:98–108.PubMedCrossRef
68.
Tamada Y, Nakajima E, Nakajima T, et al. Proteolysis of neuronal cytoskeletal proteins by calpain contributes to rat retinal cell death induced by hypoxia. Brain Res. 2005;1050:148–55.PubMedCrossRef
69.
Huang W, Fileta J, Rawe I, Qu J, Grosskreutz CL. Calpain activation in experimental glaucoma. Invest Ophthalmol Vis Sci. 2010;51:3049–54.PubMedCrossRef
70.
Hwang IK, Yoo KY, Kim DW, et al. AlphaII-spectrin breakdown product increases in principal cells in the gerbil main olfactory bulb following transient ischemia. Neurosci Lett. 2008;435:251–6.PubMedCrossRef
71.
Farkas O, Polgár B, Szekeres-Barthó J, et al. Spectrin breakdown products in the cerebrospinal fluid in severe head injury–preliminary observations. Acta Neurochir (Wien). 2005;147:855–61.CrossRef
72.
Brophy GM, Pineda JA, Papa L, et al. alphaII-Spectrin breakdown product cerebrospinal fluid exposure metrics suggest differences in cellular injury mechanisms after severe traumatic brain injury. J Neurotrauma. 2009;26:471–9.PubMedCrossRef
73.
Mattson MP. Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. Antioxid Redox Signal. 2006;8:1997–2006.PubMedCrossRef
74.
Raynaud F, Marcilhac A. Implication of calpain in neuronal apoptosis. A possible regulation of Alzheimer's disease. FEBS J. 2006;273:3437–43.PubMedCrossRef
75.
Levy OA, Malagelada C, Greene LA. Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis. 2009;14:478–500.PubMedCrossRef
76.
Vicencio JM, Lavandero S, Szabadkai G. Ca2+, autophagy and protein degradation: thrown off balance in neurodegenerative disease. Cell Calcium. 2010;47:112–21.PubMedCrossRef
77.
Mouatt-Prigent A, Karlsson JO, Agid Y, Hirsch EC. Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death? Neuroscience. 1996;73:979–87.PubMedCrossRef
78.
Alvira D, Ferrer I, Gutierrez-Cuesta J, et al. Activation of the calpain/cdk5/p25 pathway in the girus cinguli in Parkinson's disease. Parkinsonism Relat Disord. 2008;14:309–13.PubMedCrossRef
79.
Dufty BM, Warner LR, Hou ST, et al. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am J Pathol. 2007;170:1725–38.PubMedCrossRef
80.
Gafni J, Ellerby LM. Calpain activation in Huntington's disease. J Neurosci. 2002;22:4842–9.PubMed
81.
Kim YJ, Yi Y, Sapp E, et al. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc Natl Acad Sci U S A. 2001;98:12784–9.PubMedCrossRef
82.
Wellington CL, Ellerby LM, Gutekunst CA, et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J Neurosci. 2002;22:7862–72.PubMed
83.
Gafni J, Hermel E, Young JE, et al. Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J Biol Chem. 2004;279:20211–20.PubMedCrossRef
84.
Nilsson E, Alafuzoff I, Blennow K, et al. Calpain and calpastatin in normal and Alzheimer-degenerated human brain tissue. Neurobiol Aging. 1990;11:425–31.PubMedCrossRef
85.
Saito K, Elce JS, Hamos JE, Nixon RA. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci U S A. 1993;90:2628–32.PubMedCrossRef
86.
•• Higuchi M, Iwata N, Matsuba Y, et al. Mechanistic involvement of the calpain-calpastatin system in Alzheimer neuropathology. FASEB J. 2011; doi:10.​1096/​fj.​11-187740. This study reports that cerebrospinal fluid from patients with AD contained a higher level of calpain-cleaved spectrin than that of control patients.
87.
Rohn TT, Head E. Caspase activation in Alzheimer's disease: early to rise and late to bed. Rev Neurosci. 2008;19:383–93.PubMed
88.
Garg S, Timm T, Mandelkow EM, et al. Cleavage of Tau by calpain in Alzheimer's disease: the quest for the toxic 17 kD fragment. Neurobiol Aging. 2011;32:1–14.PubMedCrossRef
89.
Gaczyńska M. Changes in proteolytic susceptibility of human erythrocyte membrane proteins during red blood cell aging. Cytobios. 1992;72:197–200.PubMed
90.
Lee A, Morrow JS, Fowler VM. Caspase remodeling of the spectrin membrane skeleton during lens development and aging. J Biol Chem. 2001;276:20735–42.PubMedCrossRef
91.
Bahr BA, Vanderklish PW, Ha LT, et al. Spectrin breakdown products increase with age in telencephalon of mouse brain. Neurosci Lett. 1991;131:237–40.PubMedCrossRef
92.
Bernath E, Kupina N, Liu MC, et al. Elevation of cytoskeletal protein breakdown in aged Wistar rat brain. Neurobiol Aging. 2006;27:624–32.PubMedCrossRef
93.
Ayala-Grosso C, Tam J, Roy S, et al. Caspase-3 cleaved spectrin colocalizes with neurofilament-immunoreactive neurons in Alzheimer's disease. Neuroscience. 2006;141:863–74.PubMedCrossRef
94.
•• Liang B, Duan BY, Zhou XP, et al. Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Biol Chem. 2010;285:27737–44. This study shows elevation of calpain-mediated SBDPs in the brain in a transgenic model of AD, and attenuation of amyloid plaque pathogenesis and tau phosphorylation by in vivo inhibition of calpain activity.PubMedCrossRef
95.
Zhang XM, Cai Y, Xiong K, et al. Beta-secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development. Eur J Neurosci. 2009;30:2271–83.PubMedCrossRef
Metadata
Title
Spectrin Breakdown Products (SBDPs) as Potential Biomarkers for Neurodegenerative Diseases
Authors
Xiao-Xin Yan
Andreas Jeromin
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
Current Geriatrics Reports / Issue 2/2012
Electronic ISSN: 2196-7865
DOI
https://doi.org/10.1007/s13670-012-0009-2

Other articles of this Issue 2/2012

Current Geriatrics Reports 2/2012 Go to the issue

Biomarkers in the Classification of Biological Health and Disease Aging (Y Shen, Section Editor)

Neuropsychological Parameters as Potential Biomarkers for Alzheimer’s Disease

Biomarkers in the Classification of Biological Health and Disease Aging (Y Shen, Section Editor)

Biomarkers of Cognitive Training Effects in Aging

Biomarkers in the Classification of Biological Health and Disease Aging (Y Shen, Section Editor)

Use of Telomere Length as a Biomarker for Aging and Age-Related Disease

Biomarkers in the Classification of Biological Health and Disease Aging (Y Shen, Section Editor)

Potential Blood Biomarkers in Age-related Cerebral Small Vessel Disease

Biomarkers in the Classification of Biological Health and Disease Aging (Y Shen, Section Editor)

An Overview of Endogenous Catechol-Isoquinolines and Their Related Enzymes: Possible Biomarkers for Parkinson’s Disease

Biomarkers in the Classification of Biological Health and Disease Aging (Y Shen, Section Editor)

The Analytical Aspects and Regulatory Challenges of Biomarker Discovery: Examples from the Field of Neurodegeneration
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits